Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$13.61 USD

13.61
2,203,160

+0.41 (3.11%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $13.61 0.00 (0.00%) 6:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inogen (INGN) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.

QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance

by Zacks Equity Research

According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

by Zacks Equity Research

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Riya Anand headshot

3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

by Riya Anand

Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

by Zacks Equity Research

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

BD's (BDX) Digital Marketplace Set to Improve User Experience

by Zacks Equity Research

BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.

Philips (PHG)-Cognizant Collaborate to Develop Health Solutions

by Zacks Equity Research

Philips (PHG) is collaborating with Cognizant to develop health solutions that will help healthcare and life science companies provide improved patient care and accelerate clinical trial procedure.

McKesson (MCK) Enters Deal to Divest Some European Businesses

by Zacks Equity Research

McKesson (MCK) to sell off some of its European ventures to streamline its business and prioritize investments in areas where it has better expertise.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

by Zacks Equity Research

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Masimo (MASI) Reports Study Findings Backing the SedLine

by Zacks Equity Research

Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

by Zacks Equity Research

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden

by Zacks Equity Research

Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.

5 Top-Performing Liquid Stocks for Attractive Returns in 2021

by Zacks Equity Research

Here are five top-ranked liquid stocks -- Intuit (INTU), National Vision (EYE), Lindsay Corporation (LNN), Magnolia Oil & Gas (MGY) and Buckle (BKE) -- which investors can tap for attractive returns.

Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.

by Zacks Equity Research

Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.

West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

Bowen Center Expands Access to Care via NextGen's (NXGN) Platform

by Zacks Equity Research

NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.

Amedisys' (AMED) Contessa Buyout to Boost Home Health Business

by Zacks Equity Research

Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.

3 Reasons to Add AMN Healthcare (AMN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about AMN Healthcare (AMN) due to its broad array of services and strength in staffing service.

Trina Mukherjee headshot

3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic

by Trina Mukherjee

Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.

Abbott (ABT) CE-Marked Panbio Test Now Widely Offered in Europe

by Zacks Equity Research

Abbott's (ABT) Panbio COVID-19 Antigen Self-Test is expected to facilitate mass screenings and aid in resumption of daily life activities with the gradual reopening of economies worldwide.

Abbott (ABT) Reports Late-Breaking Data on FreeStyle Libre

by Zacks Equity Research

Late-breaking data on Abbott's (ABT) FreeStyle Libre system demonstrates improvement in health and equity outcomes for diabetes patients.

Charles River (CRL) Advances in Gene Therapy With Vigene Buyout

by Zacks Equity Research

The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.